What is the active ingredient in Ebglyss?
Ebglyss (ebganlumab-gdnn) contains ebganlumab as its active ingredient. This is a human IgG1 kappa monoclonal antibody that targets the IL-13 receptor subunit alpha-1 (IL-13Rα1), blocking signaling of IL-13 and IL-4 cytokines involved in atopic dermatitis inflammation.[1]
How does Ebglyss work for atopic dermatitis?
Ebganlumab binds specifically to IL-13Rα1, preventing IL-4 and IL-13 from activating the receptor complex. This disrupts type 2 inflammation pathways that drive skin barrier dysfunction and itching in moderate-to-severe atopic dermatitis. It's administered via subcutaneous injection, typically 400-600 mg every 2-4 weeks after an initial loading dose.[1][2]
Who makes Ebglyss and when was it approved?
Eli Lilly and Company developed and manufactures Ebglyss. The FDA approved it in September 2024 for adults and children 12+ with moderate-to-severe atopic dermatitis unresponsive to topical therapies.[1]
How does Ebglyss compare to Dupixent and other IL-13/IL-4 blockers?
Unlike Dupixent (dupilumab), which targets the IL-4Rα subunit shared by both IL-4 and IL-13 pathways, Ebglyss selectively hits IL-13Rα1. This may reduce off-target effects on other cytokines. Phase 3 trials showed similar itch reduction and skin clearance rates to Dupixent at 16 weeks (about 40-50% achieving clear/almost clear skin), but with potentially faster onset.[2][3]
| Drug | Active Ingredient | Target | Dosing Frequency |
|------|-------------------|---------|------------------|
| Ebglyss | Ebganlumab | IL-13Rα1 | Every 2 weeks |
| Dupixent | Dupilumab | IL-4Rα | Every 2-4 weeks |
| Lebrikizumab (Ebglyss competitor) | Lebrikizumab | IL-13 | Every 2-4 weeks |
What side effects do patients report?
Common reactions include injection-site reactions (up to 10%), herpes infections, and conjunctivitis (5-7%). Serious risks involve hypersensitivity and eye inflammation; eye exams are recommended. Long-term data is limited post-2024 approval.[1]
When do Ebglyss patents expire?
Key U.S. patents for ebganlumab cover composition-of-matter and methods of use, expiring between 2037-2041. No Paragraph IV challenges are listed yet on DrugPatentWatch.com.[4]
[1]: FDA Label - Ebglyss (ebganlumab-gdnn)
[2]: Lilly Press Release, September 2024
[3]: NEJM Phase 3 Trial (ADvocate1/2), 2024
[4]: DrugPatentWatch.com - Ebglyss Patents